Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

In the published article, there was an error in Table 1 (Effects of substituted group R1 and R2 on enzyme inhibition) as published. The figures A-C insert in Table 1 were found to be incorrect. The corrected Table 1 and its caption appear below.

Table 1.

Effects of substituted group R¹ and R² on enzyme inhibition.

compound	R1	R2	% enzyme inhibition
			MDM2	HDAC
7a	H	Ph	39	69
7b	5-Me	Ph	45	71
7c	5-F	Ph	51	68
7d	5-Cl	Ph	49	67
7e	5-Br	Ph	48	72
7f	6-Cl	Ph	65	64
7g	6-Br	Ph	59	68
7h	7-Me	Ph	23	71
7i	7-Br	Ph	30	67
7j	5-OMe	Ph	50	70
7k	6-OMe	Ph	54	70
7l	H	3-OMe-C6H4	44	62
7m	H	4-NMe2-C6H4	40	68
7n	H	3-Br-C6H4	43	69
7w	6-Cl	3-OMe-C6H4	60	69
7x	6-Cl	4-F-C6H4	62	73
7y	6-Cl	4-NMe2-C6H4	54	71
15b	6-Cl	2-furyl	48	70
15c	6-Cl	2-thienyl	49	70

In addition, there was an error in Table 2 (Effects of amino acids 3 on enzyme inhibition) as published. The figures A-C insert in Table 2 were found to be incorrect. The corrected Table 2 and its caption appear below.

Table 2.

Effects of amino acids 3 on enzyme inhibition.

compound	R3	R4	R5	% enzyme inhibition
				MDM2	HDAC
7f	C	C	S	65	64
7t	C	C	C	61	61
13a	C	H	/	52	65
15a	H	Ph	/	67	61

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.